1. Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
- Author
-
Masamichi Komatsu, Hiroshi Yamamoto, Kei Sonehara, Jumpei Akahane, Masayuki Hanaoka, Kazunari Tateishi, and Taisuke Araki
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Case Report ,Pembrolizumab ,medicine.disease ,Non-small cell lung cancer ,Immune-related adverse events ,Internal medicine ,medicine ,Adrenal insufficiency ,In patient ,Non small cell ,Lung cancer ,business ,RC254-282 - Abstract
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the first-line treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE.
- Published
- 2021